Critical Issues America in Endografting

This conference will help participants identify and manage complications associated with endovascular and open repair of complex aortic disease.  Topics include :
- Arch descending thoracic
- TAAA
- Pararenal and juxtarenal aneurysms
- Aortoiliac aneurysms & other miscellaneous pathologies affecting the aorta. 
- CIA will recognize potential treatment failure and the role of advance imaging techniques in the evaluation treatment and management of aortic disease.
 

A new study published online in JACC: Cardiovascular Interventions reveals that delays in recognizing symptoms of heart attack patients and seeking treatment are associated with increased damage to the heart.

In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient randomized clinical trial will compare the MiStent SES sirolimus eluting absorbable polymer coronary stent system to Abbott’s Xience stent.

XENiOS announced that its i-COR Synchronized Cardiac Assist system protects left ventricular (LV) function compared to continuous-flow ECLS (extracorporeal life support) in cardiogenic shock.

January 7, 2016 — Celyad announced Dec. 21 that the U.S. Food and Drug Administration (FDA) has authorized the company’s Investigational New Drug (IND) application for the CHART-2 trial in the United States. The phase III heart failure trial will initiate clinical testing of Celyad’s C-Cure cardiopoietic cells delivered via the C-Cath proprietary catheter.

Roxwood Medical Inc. reported that more than 500 patients have been successfully treated as part of the initial limited release of its MicroCross Catheter, the latest addition to Roxwood Medical’s expanding product line. The MicroCross Catheter is U.S. Food and Drug Administration (FDA)-cleared and offered in two sizes (Micro14 and Micro18) for use in the coronary and peripheral vasculatures, providing enhanced guidewire support through challenging and tortuous anatomy.

Stroke is the third leading cause of death in the Western industrialized world, and according to the Centers for Disease Control (CDC), accounts for one of every 19 deaths in the United States each year. Over 80 percent of strokes are ischemic in nature, caused by clots and other obstructions in vessels that supply blood to the brain, and cardiac embolism accounts for approximately one-third of all cases of ischemic stroke. Echocardiography in general and transesophageal echocardiography in particular are essential for evaluation, diagnosis and management of stroke and systemic embolism. A new document, Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism, will appear in the January 2016 issue of the Journal of the American Society of Echocardiography (JASE) and provides the first set of guidelines from the American Society of Echocardiography (ASE) specific to this topic.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now